Tango Therapeutics Inc TNGX

$21.73 -0.98 (-4.32%)

Valuation

Market cap
3,682,257,000
Revenue TTM
$62,380,000
Net income TTM
$-101,590,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-162.86%
Debt to equity
0.00

Trading

Volume
1,740,700
Avg volume
3,720,562
Day's range
$21.63 – $23.05
Shares out
169,455,000
Stochastic %K
9%
Beta
1.26
Analysts
Strong Buy
Price target
$44.75

Price

Company profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for t...

Show more

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 320 4900
Website
https://www.tangotx.com
Address
201 Brookline Avenue, Suite 901, Boston, United States

Latest news

No headlines yet.